The role of preoperative PSA level in prostate cancer

Yelda Dere, İlker Akarken, Hayrettin Şahin


Background: PSA levels between 0-4 ng/ml is generally accepted as normal range, there is no world widely accepted cut-off value. PSA level is most commonly used for determining patients to whom needle biopsy should be performed. Authors aimed to investigate the relationship between preoperative PSA level and histopathological features.

Methods: Ninety prostatic adenocarcinoma cases diagnosed between January 2013 and January 2018 and treated by RP were included. Patients had no measurement of PSA before the operation were excluded from the study. Patients were grouped according to preoperative PSA as low-risk (<10 ng/ml), medium-risk (10-20 ng/ml) and high-risk (>20 ng/ml). The relations between all of the histopathological parameters were analyzed in addition to the preoperative PSA levels.

Results: The mean age and preoperative PSA level was found as 64.16, and 12.33, respectively. The presence of EPE and tumour positive base margin showed significant relation among PSA groups as well as the presence of lymphovascular invasion and the involvement of the seminal vesicles. Intracytoplasmic mucin and foamy cytoplasm was more common in low-risk PSA group and the difference was significant.

Conclusions: PSA level is one of the most commonly used marker for predicting high risk patients before the operation however it may also show relation with various histopathological factors that have effect on the prognosis of prostatic adenocarcinoma.


Histopathology, Prostate cancer, Prostate specific antigen

Full Text:



Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51(1):15-36.

Buhmeida A, Pyrhönen S, Laato M, Collan Y. Prognostic factors in prostate cancer. Diag Path. 2006;1:4.

Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, et al. The University of California, San Francisco Cancer of the prostate risk assessment score: a straightforward and reliable preoperative indicator of disease recurrence after radical prostatectomy. J Urol. 2005;173(6):1938-42.

Björk T, Lilja H, Christensson A. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer. BJU Int. 1999;84:1021-7.

Humprey PA, Egevad L, Netto G, Amin MB, Epstein JI, Rubin MA, et al. Acinar adenocarcinoma, Tumors of the prostate. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE, eds. WHO classification of tumours of the urinary system and male genital organs. 4th ed. IARC, Lyon; 2016;3:138-162.

Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humprey PA, the grading committee. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma definition of grading patterns and proposal for a new grading system. Am J of Surg Pathol. 2016;40(2):244-52.

Noiwan S, Rattanarapee S. Mucin production in prostatic adenocarcinoma: a retrospective study of 190 radical prostatectomy and/or core biopsy specimens in department of pathology, Siri raj Hospital, Mahidol University, Thailand. J Med Assoc Thailand= Chotmaihet thangphaet. 2011 Feb;94(2):224-30.

Freedland SJ, Presti JC, Kane CJ, Aronson WJ, Terris MK, Dorey F, et al. Do younger men have better biochemical outcomes after radical prostatectomy? Urol. 2004;63(3):518-22.

Ito K, Nakashima J, Mukai M, Asakura H, Ohigashi T, Saito S, et al. Prognostic implication of microvascular invasion in biochemical failure in patients treated with radical prostatectomy. Urologia Internationalis. 2003;70(4):297-302.

Dema A, Taban S, Lazar E, Borda A, Lazureanu C, Herman D, et al. Pseudo benign prostate carcinomas: causes of false-negative biopsy results. Rom J Morphol Embryol. 2011;52(3 Suppl):963-74.

Warrick JI, Humphrey PA. Foamy gland carcinoma of the prostate in needle biopsy: incidence, gleason grade, and comparative a-methylacyl-coa racemase vs. ERG expression. Am J Surg Pathol. 2013;37(11):1709-14.

Berman DM, Yang J, Epstein JI. Foamy gland high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol. 2000;24(1):140-4.